Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-QuadCAR01-T in Relapsed or Refractory B-cell Malignancies
NCT07284433Phase 2Recruiting
- Sponsor
- AvenCell Therapeutics
- Start
- Jan 2026
- Primary completion
- Apr 2029
- Modality
- CRISPR-Cas9, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of AVC-203 in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), sponsored by AvenCell Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
AVC-203
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07284433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284433.